MRD conversion during oral azacitidine maintenance correlates with outcomes in predominantly favorable-risk AML
Oral cancer drug may maintain remission in patients whose disease becomes undetectable, with monitoring guiding treatment decisions in this patient group.
In this multicenter real-world retrospective study (n=30) of favorable-risk AML patients on oral azacitidine maintenance, MRD conversion to negativity during therapy was associated with RFS comparable to patients already MRD-negative at initiation, while persistent MRD predicted early relapse. The findings are hypothesis-generating given the small sample size but support prospective MRD-guided maintenance strategies.
What the study was
- Study design
- Multicenter real-world retrospective study; Israel Acute Leukemia Group
- Population
- AML patients in first complete remission on oral azacitidine maintenance; predominantly ELN favorable-risk; Israel multicenter
- Sample size
- 30
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Annals of Hematology
Why it surfaced
Real-world data on oral azacitidine MRD dynamics in AML; clinically actionable if confirmed. Design is retrospective, n=30 is small; authors explicitly note hypothesis-generating.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.